

Variability of exhaled breath condensate leukotriene B₄ and 8-isoprostane in COPD patients

Zoë L Borrill
R Cerys Starkey
S Dave Singh

Medicines Evaluation Unit, Langley Building, Manchester University Wythenshawe Hospital, Manchester M23 9LT, UK

Abstract: The reproducibility of exhaled breath condensate (EBC) mediators is not well documented in chronic obstructive pulmonary disease (COPD). This study assessed within assay (WA), within (WD) and between day (BD) reproducibility of EBC leukotriene B₄ (LTB₄) and 8-isoprostane. Three EBC samples were collected from 24 COPD patients separated by 1 h and 1 wk, to assess WD and BD reproducibility. WA reproducibility was assessed by sample analysis by enzyme immunoassay in triplicate. WA coefficient of variation for LTB₄ and 8-isoprostane (18.2% and 29.2%, respectively) was lower than corresponding values for WD (47.7% and 65.3%, respectively) and BD (75.7% and 79.1%, respectively). Repeatability coefficient for 8-isoprostane and LTB₄ assays were 18.6 pg/ml and 13.2 pg/ml, respectively. Group mean differences for WD and BD were small and statistically nonsignificant. Using the Bland Altman method, there were wide limits of agreement for WD (−51.6 to 47.2 for 8-isoprostane and −31.8 to 31.4 for LTB₄) and BD reproducibility (−61.4 to 75.7 for 8-isoprostane and −29.3 to 38.6 for LTB₄). This is the first study to fully report the variability of EBC 8-isoprostane and LTB₄ in COPD. WA variability and group mean changes were small. However, we observed considerable WD and BD variability for these biomarkers.

Keywords: chronic obstructive pulmonary disease, exhaled breath condensate, leukotriene B₄, 8-isoprostane, reproducibility.

Introduction

Biomarkers of airway inflammation and oxidative stress can be measured noninvasively using exhaled breath condensate (EBC) sampling of airway lining fluid. Leukotriene B₄ (LTB₄), a potent neutrophil chemoattractant, and 8-isoprostane, which is formed during oxidative stress conditions by free-radical peroxidation of arachidonic acid, are examples of biomarkers that have been measured in EBC from chronic obstructive pulmonary disease (COPD) patients. The absolute concentration of these mediators has varied greatly between studies, despite use of identical immunoassay methods. For example, mean values of LTB₄ in COPD patients have ranged from 10 pg/ml (Biernacki et al 2003) to 100 pg/ml (Montuschi et al 2003). Similarly, mean values of 8-isoprostane in COPD patients have ranged from 9 pg/ml (Biernacki et al 2003) to 47 pg/ml (Kostikas et al 2003). The disparity between published findings may be attributable to the small sample sizes often used, or to method variability. The reproducibility of EBC LTB₄ and 8-isoprostane has not been well documented in COPD patients. This issue was highlighted as an important area for future research by the recent American Thoracic Society/European Respiratory Society (ATS/ERS) task force document on EBC methodology (Hovarth et al 2005). The current study was designed to investigate the variability of these mediators in COPD patients.

Correspondence: Zoë L Borrill
Medicines Evaluation Unit, Langley Building, Manchester University Wythenshawe Hospital, Manchester M23 9LT, UK
Tel +44 161 946 4050/4073
Fax +44 161 946 1459
Email zborrill@meu.org.uk

Methods

Twenty-four patients with COPD (16 male, mean age 65; 10 current smokers, mean pack years 40; mean % predicted forced expiratory volume in one second [FEV₁] 54% standard deviation [SD] 13.5%) diagnosed according to current criteria (NCCCC 2004) were recruited. Exclusion criteria were history of asthma or atopy, and respiratory tract infection within 2 weeks of sample collection. Subjects were asked to refrain from caffeine and cigarettes for 2 hours prior to each visit. Written informed consent was obtained and the local ethics committee approved the study.

Three aspects of reproducibility were studied in all subjects: 1) Within day (WD) reproducibility was assessed by the collection of 2 samples of EBC separated by 1 h. 2) Between day (BD) reproducibility was assessed by the collection of a further EBC sample 1 week later; this measurement was compared with the first collection one week earlier. 3) Within array (WA) reproducibility was assessed by analysis in triplicate of each sample. EBC was collected during tidal breathing for 10 minutes without a nose peg (EcoScreen, Jaegar, Hoechberg, Germany). Subjects were instructed to breathe normally through their mouth and to temporarily discontinue collection if they needed to swallow saliva or cough. Samples were aliquoted into separate 200 µl tubes and frozen at -80°C. LTB₄ and 8-isoprostane were measured by enzyme immunoassays (Cayman Chemical, Ann Arbor, MI, USA). All samples were analysed in triplicate. The lower limits of detection were 13 pg/ml and 5 pg/ml for LTB₄ and 8-isoprostane respectively. Samples with a concentration below the limit of the assay were assigned a level of 0 pg/ml.

Three statistical approaches were used to assess variability: 1) Coefficient of variation was used to assess WD, BD, and WA variability. 2) The repeatability coefficient was used to analyse within assay variation; this estimated the limits of the differences that can be expected to occur between 95% of repeated assays performed on the same sample. Similarly, the Bland-Altman method with limits of agreement was used to assess WD and BD variability; this estimates the differences that can be expected to occur between 95% of samples collected at different times from the same subject (Bland and Altman 1986). The group mean and 95% confidence intervals for the WD and BD differences were determined.

Results

The coefficients of variation are shown in Table 1; the WA coefficient of variation for both LTB₄ and 8-isoprostane was lower than the corresponding values for WD and BD variability. The repeatability coefficient for the 8-isoprostane

Table 1 Coefficient of variation for within assay, within day, and between day variability

| | Within assay | Within day | Between day |
|------------------|--------------|------------|-------------|
| 8-isoprostane | 18.2% | 49.7% | 75.7% |
| LTB ₄ | 29.2% | 65.3% | 79.1% |

assay was 18.6 pg/ml and for the LTB₄ assay was 13.2 pg/ml. Group mean differences for WD and BD changes were small (Table 2). In contrast, the limits of agreement for WD and BD variability were large, demonstrating that levels of LTB₄ and 8-isoprostane can change markedly in some individuals even within 1 h (Table 2; Figure 1, 2). Limits of agreement for current smokers were in some cases wider than those for ex-smokers for both 8-isoprostane and LTB₄ (Table 3).

Discussion

This is the first study to fully report the variability of EBC 8-isoprostane and LTB₄ in COPD patients. Using the Bland Altman method, a robust technique for quantifying the potential variability during repeated sampling from the same subject, we observed considerable WD and BD variability for these biomarkers. Previous studies using these biomarkers have either failed to investigate intra-subject variability or have reported variability as being 'minimal'. There are several reasons why the variability of EBC mediators may have been underestimated in these studies. Firstly, EBC variability has been studied in healthy subjects (Csoma et al 2002). It is probable that within subject variability in patients with lung inflammation will be higher. Secondly, the use of the coefficient of variation and correlation coefficients provide statistics using arbitrary values that do not relate to the units of the measurement being studied. Thirdly, coefficient of variation, correlation coefficients and group mean statistics provide information about overall group differences. These types of analysis do not inform us of the potential for

Table 2 Mean difference (95% CI) and limits of agreement (LA) for within and between day variability of 8-isoprostane and LTB₄ in COPD

| | 8-isoprostane (pg/ml) | LTB ₄ (pg/ml) |
|--------------------------------------|-----------------------|--------------------------|
| Within day mean difference (95% CI) | -2.2 (-12.1 to 7.7) | -0.2 (-6.5 to 6.1) |
| Within day LA | -51.6 to 47.2 | -31.8 to 31.4 |
| Between day mean difference (95% CI) | 7.1 (-6.6 to 20.8) | 4.7 (-2.1 to 11.4) |
| Between day LA | -61.4 to 75.7 | -29.3 to 38.6 |

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; LTB₄, leukotriene B₄.





Figure 1 Bland Altman plots for (A) within day and (B) between day variability of EBC 8-isoprostane. Mean 8-isoprostane plotted against difference between 2 EBC samples taken 1 hour and 1 week apart.
Abbreviations: EBC, exhaled breath condensate.





Figure 2 Bland Altman plots for (A) within day and (B) between day variability of EBC LTB₄. Mean LTB₄ plotted against difference between 2 EBC samples taken 1 hour and 1 week apart.

Abbreviations: EBC, exhaled breath condensate; LTB₄, leukotriene B₄.

Table 3 Mean difference (limits of agreement) for within day and between day variability of 8-isoprostane and LTB₄ in COPD in ex- and current smokers

| | | Within day | Between day |
|------------------|-----------------|----------------------|-----------------------|
| 8-isoprostane | Ex-smokers | 3.9 (-35.1 to 42.8) | -0.1 (-65.3 to 65.1) |
| | Current smokers | 17.3 (-54.6 to 88.6) | -10.7 (-69.8 to 48.5) |
| LTB ₄ | Ex-smokers | 2.1 (-30.1 to 34.3) | 2.5 (-24.4 to 29.5) |
| | Current smokers | -3.4 (-34.7 to 27.8) | 7.6 (-35.1 to 50.3) |

Abbreviations: COPD, chronic obstructive pulmonary disease; LTB₄, leukotriene B₄.

repeated samples from a single individual to vary over time. In the current study we observed no significant change in the group mean values over time. This does not mean that there was no variability; the Bland Altman method graphically shows that while some individuals have highly reproducible measurements over time, there was considerable variation in the samples from other subjects, which contributed to the wide limits of agreements. The interpretation of the limits of agreements is, for example, that repeated 8-isoprostane sampling on different days can be expected to vary from -61.4 pg/ml to 75.7 pg/ml in an individual simply due to natural variability. Using this assay as a biomarker to detect a significant biological change (greater than assay variability) in an individual, such as an exacerbation, would require a change greater than these limits of agreement.

The variability observed in this study may be explained either by (1) true changes in the composition of the airway lining fluid, (2) variability due to the sample collection methodology, or (3) the variability of the immunoassay method used to analyse the sample. The contribution of these 3 factors will now be considered: 1) We have recently shown marked WD and BD variability of EBC pH in COPD patients compared with that seen in healthy subjects, indicating that there are changes in the composition of EBC in COPD patients over time (Borrill et al 2005). In the current study, there was some evidence of greater variability in current smokers compared with ex-smokers. Acute smoking was found to cause an increase in EBC 8-isoprostane after 15 minutes, but not at 5 h (Montuschi et al 2000). In the current study, variation in the time since the last cigarette may have contributed to the variability observed. 2) Inconsistencies in the rate of aerosolization of airway lining fluid during sample collection may lead to increased variability. Attempts have been made to correct for this using dilution factors (Effros et al 2003) and further study in this area is required. 3) The coefficient of variation showed lower within assay variability for both LTB₄ and 8-isoprostane compared with within subject variation. This was confirmed by the repeatability coefficients for each assay which were lower than the limits

of agreement between samples. The numerical value of the repeatability coefficient can be considered to be equivalent to the magnitude of the limits of agreement, which enables direct comparison. This indicates that the repeatability of the assay itself cannot fully explain the degree of within subject variability observed.

In a study by van Hoydonk and colleagues (2004), 8-isoprostane was undetectable in 21 of the 36 samples from healthy smokers. In the current study 8-isoprostane was detectable in all COPD samples. However, levels of LTB₄ were below the limit of detection in a large number of samples, which may indicate the poor sensitivity of this assay. In a study by Carpagnano and colleagues (2003) some samples had levels which were below the limit of detection of the assay. This suggests that the authors either diluted the standard below the level recommended, or that they extrapolated the standard curve below the lowest concentration of standard. These are not standard practices for immunoassays and are likely to lead to a loss of accuracy. To avoid these potential errors, we defined the lower limit of detection of the assay as the lowest concentration on the standard curve. Methods such as mass spectroscopy may offer advantages over immunoassays in terms of increased sensitivity and reduced variability (Cap et al 2004; Montuschi et al 2004).

Overall, it is likely that the variability we have reported is multifactorial, with changes in the composition of the airway lining fluid, variability due to the sample collection methodology, and immunoassay variability and sensitivity all contributing. The high level of variability observed casts doubt on the current EBC methodology used to assess LTB₄ and 8-isoprostane. Our study highlights the importance of assessing method variability. Differences between patients with disease and controls can only be properly evaluated with knowledge of the variability of the method.

References

- Biernacki WA, Kharitonov SA, Barnes PJ. 2003. Increased leukotriene B₄ and 8-isoprostane in exhaled breath condensate of patients with exacerbation of COPD. *Thorax*, 58:294-8.

- Bland JM, Altman DG. 1986. Statistical methods for assessing agreement between 2 methods of clinical measurement. *Lancet*, 1:307–10.
- Borrill Z, Starkey C, Vestbo J, et al. 2005. Reproducibility of exhaled breath condensate pH in chronic obstructive pulmonary disease. *Eur Respir J*, 25:269–74.
- Cap P, Chladek J, Pehal F, et al. 2004. Gas chromatography/mass spectrometry analysis of exhaled leukotrienes in asthmatic patients. *Thorax*, 59:465–70.
- Carpagnano GE, Kharitonov SA, Foschino-Barbaro MP, et al. 2003. Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. *Eur Respir J*, 21:589–93.
- Csoma ZS, Kharitonov XA, Balint B, et al. 2002. Increased leukotrienes in exhaled breath condensate in childhood asthma. *Am J Respir Crit Care Med*, 166:1345–9.
- Effros RM, Biller J, Foss B, et al. 2003. A simple method for estimating respiratory solute dilution in exhaled breath condensates. *Am J Respir Crit Care Med*, 168:1500–15.
- Horvath I, Hunt J, Barnes PJ, et al; ATS/ERS Task Force on Exhaled Breath Condensate. 2005. Exhaled breath condensate: methodological recommendations and unresolved questions. *Eur Respir J*, 26:523–48.
- Kostikas K, Papatheodorou G, Psathakis K, et al. 2003. Oxidative stress in expired breath condensate in patients with COPD. *Chest*, 124:1373–80.
- Montuschi P, Collins JV, Ciabattoni G, et al. 2000. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. *Am J Respir Crit Care Med*, 162:1175–7.
- Montuschi P, Kharitonov SA, Ciabattoni G, et al. 2003. Exhaled leukotrienes and prostaglandins in COPD. *Thorax*, 58:585–8.
- Montuschi P, Martello S, Felli M, et al. 2004. Ion trap chromatography/tandem mass spectrometry analysis of leukotriene B₄ in exhaled breath condensate. *Rapid Commun Mass Spectrom*, 18:2723–29.
- [NCCCC] National Collaborating Centre for Chronic Conditions. 2004. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. *Thorax* 2004; 59(Suppl 1):1–232.
- van Hoydonck PGA, Wuyts WA, Vanaudenaerde BM, et al. 2004. Quantitative analysis of 8-isoprostane and hydrogen peroxide in exhaled breath condensate. *Eur Respir J*, 23:189–92.